<?xml version="1.0" encoding="UTF-8"?>
<ArticalData xmlns="http://www.consortiumpublisher.com">
  <Header>
    <ArticleTitle>ROLE OF HIGH DOSE ASPIRIN IN MODULATING HYPERLIPIDEMIA AND HYPERGLYCEMIA</ArticleTitle>
  </Header>
  <ArticleParameters>
    <ArticleReceivingDate>2010-09-05</ArticleReceivingDate>
    <ArticleRevisedDate>2010-09-15</ArticleRevisedDate>
    <ArticleAcceptanceDate>2010-10-25</ArticleAcceptanceDate>
    <ArticlePublishedOn>3/19/2025 2:05:17 PM</ArticlePublishedOn>
    <Journal>Journal of Applied Pharmacy</Journal>
    <Volume>2</Volume>
    <Year>2010</Year>
    <ArticleType>Original research article</ArticleType>
    <FirstPage>112</FirstPage>
    <LastPage>119</LastPage>
    <CollectionYear>2010</CollectionYear>
    <PublisherId>JAppPharm (2010 ). 2. 112-119</PublisherId>
    <ArticleDoi>https://doi.org/10.21065/19204159.2.112</ArticleDoi>
    <Language>English</Language>
  </ArticleParameters>
  <Authors>
    <ArticleAuthors>Bashir Ahmad1, Uzma Saleem2, Farman Matloob Khan1, Alia Erum3, Maqsood Alam4, Saeed Mahmood5</ArticleAuthors>
  </Authors>
  <keywords>
    <Articlekeywords>Alloxan, Antihyperlipidemic, Diabetes, IKKß, Salicylates</Articlekeywords>
  </keywords>
  <Abstract>
    <ArticleAbstract>This study was designed to evaluate the antidiabetic and antihyperlipidemic effects of high dose aspirin in rabbits. Healthy rabbits were made diabetic by injecting 150mg/kg body weight of Alloxan, in normal saline solution. intravenously in the marginal ear vein for seven days. The rabbits with serum glucose levels greater than 200mg/dl were considered as diabetic and used in this study. High dose aspirin (120mg/kg) p.o. showed maximum decrease in serum triglyceride level (42.07%), serum total cholesterol level (19.36%), and serum LDL level (6.18%). Glibenclamide showed decrease in fasting blood glucose level 56.31% as compared to high dose aspirin (23.91%). In the light of these results, it is suggested that such study should be carried out in human beings to make use of agents having S inhibitory activity of kappa Kinase Beta (IKKß) pathway, which will provide a novel approach for treatment of diabetes- associated hyperlipidaemia.</ArticleAbstract>
  </Abstract>
</ArticalData>